NewAmsterdam Pharma Company N.V. (NAMS) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Naarden, Netherlands. 현재 CEO는 Michael Harvey Davidson Facp..
NAMS 을(를) 보유 IPO 날짜 2021-02-09, 68 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $3.96B.
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Naarden, the Netherlands, dedicated to developing treatments for metabolic diseases. The company's lead investigational candidate, obicetrapib, is a novel selective inhibitor of Cholesteryl Ester Transfer Protein (CETP) that has demonstrated clinical efficacy in reducing low-density lipoprotein cholesterol (LDL-C) while substantially increasing high-density lipoprotein cholesterol (HDL-C). This dual mechanism addresses a significant unmet medical need in lipid management and cardiovascular disease prevention. NewAmsterdam is focused on advancing obicetrapib through clinical development to improve patient outcomes in metabolic disease populations.
